Michael Y Lin, MD
Anesthesiology · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lin’s office at (408) 851-1000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A126712 · Current
Licensed to practise in California · since 2013 · expires 2027-02-28 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$23 in 2025
| 2025 | 1 | 1 | None | $23 |
| 2022 | 1 | 1 | None | $122 |
| 2020 | 1 | 1 | None | $113 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Incyte | Opzelura | $23 | 1 payment
|
See the published payment
| Incyte | Meals · 2025-09-08 | Opzelura | $23 |
See earlier years (2022, 2020)
2022: $122
| Integra LifeSciences | Codman Certas | $122 | 1 payment
|
2020: $113
| La Jolla Pharmaceutical | Giapreza | $113 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2024 | Their institution | $73,243 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2025 | Their institution | $65,046 |
| Incyte Corporation · A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis · 2023 | Their institution | $32,226 |
| Incyte Corporation · A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacyand Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis · 2024 | Their institution | $10,484 |
| Incyte Corporation · A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacyand Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis · 2025 | Their institution | $9,158 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2023 | Their institution | $548 |
Professional record
- NPI
- 1326305707
- Licence
- CA A126712California A126712: Current · expires 2027-02-28
- Trained
- University of California, San Francisco School of Medicine, 2012
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207LC0200X (207LC0200X); Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 700 Lawrence Expy, Santa Clara, CA, 95051
- NPI first listed
- 2012-04-23
- NPI last updated
- 2022-06-02
- NPI record certified
- 2022-06-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 757 Westwood Plz Ste 3325, Los Angeles, CA, 90095 · 8700 Beverly Blvd, West Hollywood, CA, 90048
This office lists an electronic records connection.